ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Long-Term Outcomes After Bioprosthetic Tricuspid Valve Replacement: A Multicenter Study

Thursday, April 17, 2025

Submitted by

Source

Source Name: European Journal of Cardio-Thoracic Surgery

Author(s)

Antonio Piperata, Jef Van den Eynde, Mateo Marin-Cuartas, Giacomo Bortolussi, Petr Fila, Tim Walter, Mehmet Cahit Sarıcaoğlu, Jan Gofus, Bilkhu Rajdeep, Michel Pompeu Sá, Fabrizio Rosati, Manuela De la Cuesta, Elisa Gastino, Besart Cuko, Julien Ternacle, Carlo de Vincentiis, Martin Czerny, Ahmet Rüçhan Akar, Gianluca Lucchese, Basel Ramlawi, Michael A Borger, Thomas Modine

Long-term evidence about bioprosthetic tricuspid valve replacement is scarce. This study aims to investigate the long-term clinical outcomes of patients who underwent tricuspid valve replacement with bioprostheses. This multicenter retrospective study included patients from 10 high-volume centers in seven different countries who underwent tricuspid valve replacement with bioprostheses. Echocardiographic and clinical data were reviewed, and long-term outcomes were investigated. Of the 675 patients, isolated tricuspid valve replacement was performed in 358 patients (53 percent), while 317 (47 percent) underwent concomitant procedures. Between these two groups, patients who underwent combined procedures reported a significantly higher incidence of infection, atrioventricular block, multiorgan failure, longer ICU and hospital stays, and higher 30-day mortality compared to patients who underwent isolated procedures. The overall 30-day mortality occurred in 70 patients (10.4 percent) (46 [14.6 percent] in the combined group vs 24 [6.74 percent] in the isolated group, p = 0.001). During follow-up, there was a continuous rate of attrition due to death, with cumulative incidences of death at five, 10-, and 15-years being 27.2 percent, 46.2 percent, and 60.6 percent, respectively. In contrast, the risk of reintervention started to significantly increase after 10 years of follow-up, with cumulative incidences of reintervention being 6.1 percent, 10.8 percent, and 23.3 percent, respectively. Freedom from tricuspid valve reintervention, pacemaker implantation, tricuspid valve endocarditis, and major thromboembolic events at 15 years were 56.5 percent,77.3 percent, 84.0 percent, and 86.4 percent, respectively. The authors conclude that tricuspid valve replacement with bioprostheses is an effective treatment, despite being associated with relatively high early and long-term mortality. However, the risk of structural valve degeneration rises significantly after 10 years. 

Add comment

Log in or register to post comments